Zai Lab completed a $200 million follow-on financing, just eight months after its previous $150 million follow-on round. The company expects to launch two oncology products in China this year, a PARP inhibitor and an electric fields treatment for GBM. It already markets both products in Hong Kong. It will reserve more than one-quarter of its newest funding for business development. The funding was well-received: underwriters upped the number of ADSs available from 5 million to 7.8 million in response to investor interest. More details....
Stock Symbol: (NSDQ: ZLAB)
Share this with colleagues: